Replies to post #559796 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

What exactly would these partners be getting. I'm certainly no expert, but I believe that once DCVax-L is approved it can be used with other approved products as Oncologists and patients agree to do. Putting it in combination trials with certain therapeutics may result in label changes that add to treatment protocols, but I don't know that Drs. choosing other competitive products can be prevented if that's their choice.

I believe a partnership with a BP will bring in billions, that's the kind of money that's needed to do multiple trials and handle getting our vaccine into countries all over the world. I would rather see that sort of money come from a partnership than massive dilution. A partner will probably pay a premium that's roughly double the current share price, and essentially move the share price to that level. Dilutive funding is normally done at a discount to the current share price and does little to elevate the share price. I'm not looking for either until our share price is dramatically higher, but I think we'd be well served by a BP partner that took our share price well into double digits once we got the share price well into single digits, or higher.

Gary

[biosectinvestor]

Equity can be purchased back on the open market. Royalties can never be returned. It’s not really a solution to dilution, it just is not obvious dilution. It is still reducing the pie owned by shareholders per share, but royalties never can be reduced. They are permanent. Shares can be bought back with a successful commercial business. And that leads to steady returns. Though early on, usually the best investment is directly into the business rather than to the secondary market.

They will finance at the best rates they can. If royalties offer that, then they can do it. But doubtful that any of us here can affect what terms are possible.